Your essential biotech, medtech, and pharma recap — no noise, just what matters.

⚡ Executive Takeaway

Lilly's 12th deal adds yet another modality to the most diversified pipeline build in pharma history. Ascidian's RNA exon editing technology is distinct from CRISPR, base editing, and the recombinase approaches Lilly licensed from Profluent. Exon editing works at the RNA level (no permanent DNA changes), correcting genetic defects by modifying messenger RNA before it is translated into protein. For genetic kidney diseases, where the patient population is small but the unmet need is severe, RNA exon editing could offer a reversible, titratable therapeutic approach that DNA editing cannot. The $1.9B milestone structure signals Lilly sees franchise-level potential. Separately, BMS joining the Anthropic partnership ecosystem is notable. With Sanofi, Novo, AbbVie, Novartis (Narasimhan on the board), and now BMS, Anthropic has assembled partnerships with five of the top ten global pharma companies by revenue. The Moderna Ebola vaccine partnership directly addresses the countermeasure gap we flagged when the WHO declared the Bundibugyo PHEIC on May 17. And the Germany investment pullback from Lilly and Boehringer ($1B+ each) shows how quickly pharma will redirect capital when pricing reforms threaten returns. 👉 Read Full Analysis

🔮 What To Watch

🏢 Corporate & Business Developments

Lilly's 12th Deal: $1.9B RNA Exon Editing for Kidney Disease LLY

Lilly signed a collaboration with Ascidian Therapeutics worth up to $1.9B in milestones to develop RNA exon editing therapeutics for genetic kidney diseases, according to Fierce Biotech. RNA exon editing modifies messenger RNA to correct genetic defects without making permanent changes to DNA, offering a potentially reversible and titratable approach to genetic medicine. The deal adds an eighth modality to Lilly's 2026 acquisition portfolio: GLP-1 obesity, in vivo CAR-T, narcolepsy, ADCs, myelofibrosis, AI gene editing, vaccines, and now RNA editing.

BMS Partners with Anthropic on AI Drug Development BMY

Bristol Myers Squibb announced a partnership with Anthropic to apply Claude AI across drug development workflows, according to The Medicine Maker. BMS now joins a growing roster of pharma companies working with Anthropic: Sanofi, Novo Nordisk, AbbVie, and Novartis (CEO Narasimhan sits on Anthropic's board). Anthropic also acquired Coefficient Bio for $400M in April and partnered with the Gates Foundation in May. The BMS deal extends Anthropic's reach into the hematology and oncology space where BMS has its deepest pipeline.

Moderna Partners on Bundibugyo Ebola Vaccine MRNA

Moderna linked up with a global vaccine foundation to develop a vaccine targeting the Bundibugyo Ebola strain, according to BioSpace. The partnership directly addresses the WHO PHEIC declared May 17, which involves the rare Bundibugyo variant for which no approved vaccines or therapeutics exist. Moderna's mRNA platform is theoretically among the fastest to redirect to a new pathogen target. This follows Lilly's acquisition of three vaccine companies in May (Curevo, LimmaTech, Vaccine Company) and the broader industry mobilization around infectious disease prevention.

🌍 Policy & Investment

Lilly and Boehringer Slash German Investments by $1B+ Each

Lilly and Boehringer Ingelheim each cut planned investments in Germany by at least $1B in response to a healthcare reform initiative, according to Fierce Pharma. The moves signal the sensitivity of pharma investment to pricing policy. Germany is the largest pharmaceutical market in Europe. If similar pricing reforms spread to other EU markets, additional investment redirections could follow. The timing coincides with the EU Critical Medicines Act (agreed May 22) and the administration's MFN pricing framework in the U.S. Pharma companies are increasingly directing capital to markets where the policy environment favors investment returns.

🏭 CDMO & Manufacturing

CordenPharma Acquires AmbioPharm for U.S.-Based Peptide Supply

Swiss CDMO CordenPharma agreed to acquire AmbioPharm, gaining peptide manufacturing facilities including a plant in South Carolina, according to BioSpace. The deal provides CordenPharma with fully U.S.-based peptide supply capability, relevant for GLP-1 manufacturing and other peptide therapeutics. The acquisition aligns with the Section 232 tariff framework's emphasis on domestic pharmaceutical manufacturing and the broader industry push to build U.S.-based supply chains.

📅 The Week Ahead

Updated running total:

Total: approximately $30.8B+ across 12 deals in under six months. Eight distinct modalities. Seven therapeutic areas.

💊 Anthropic's Pharma Ecosystem

Five of the top ten global pharma companies by revenue are now working with Anthropic in some capacity. No other AI company has this depth of pharma integration. The strategy is clear: Anthropic is positioning Claude as the default AI platform for pharmaceutical R&D, operations, and clinical development.

📊 20 Novel Drugs Through May 2026

RTTNews reported that the FDA has approved 20 novel drugs through the end of May 2026, including seven under the CNPV pilot program. The CNPV program, launched by Commissioner Makary (who has since resigned), continues to operate under acting commissioner Diamantas. Whether it survives the leadership transition and potential permanent commissioner appointment remains an open question.

🎯 Catalyst Calendar: June 2026 Forward

👉 Visit The Pro Hub

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →